Cognitive Impairment in Elderly People: Predisposing Factors and Implications for Experimental Drug Studies

Drugs & Aging

Volumn 7, Issue 6, 1995, Pages 459-479

  Jolles, J ^a   Verhey, F R J ^a   Riedel, W J ^a   Houx, P J ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; AGING; COGNITION; COGNITIVE DEFECT; HUMAN; MEMORY DISORDER; PSYCHOLOGICAL ASPECT; REVIEW;

AGED; AGING; COGNITION; COGNITION DISORDERS; HUMANS; MEMORY DISORDERS;

EID: 0029448037     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/00002512-199507060-00006     Document Type: Article

References (176)

1. Cognitive, emotional and behavioral dysfunctions in aging and dementia
2. Speed of behavior and its implications for cognition
3. Neuropsychological prediction of dementia and the absence of dementia in healthy elderly persons
4. Psychopharmacology and successful cerebral aging
5. French recommendations for clinical drug trials in cognitive disorders of the elderly
6. Age associated memory impairment
7. Diagnosing dementia: comparison between a monodisciplinary and a multidisciplinary approach
8. Age-related changes in memory: learning and remembering new information
9. Clinical and neuropsychological assessment of dementia
10. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD)
11. Psychometric differentiation of mild dementia of the Alzheimer type
12. Consensus conference on the methodology of clinical trials of ‘nootropics’; 1989 Jun 28–30: Munich. Report of the consensus committee
13. Muscarinic agonists for senile dementia: past experience and future trends
14. Clinical trials in Alzheimer’s disease
15. Drug treatments of dementia
16. Problem solving and decision making
17. Attention and performance: identifying and localizing age deficits
18. Arousal, sleep, and aging
19. Resource-reduction interpretations of cognitive aging
20. Rigorous health screening reduces age effect on memory scanning task
21. Applied cognitive gerontology: some problems, methodologies and data
22. Are neurons of the human cerebral cortex really lost during aging?
23. A study of the drop-out rates in longitudinal research on aging and the prediction of death
24. Development, drop, and death
25. Stroop interference: aging effects assessed with the Stroop Color-Word Test
26. Cognitive aging, biological life events and primitive reflexes
27. Effects of age and raw IQ test scores on mean correct and mean error reaction times in serial choice tasks: a reply to Smith & Brewer
28. Performance measures of 16- to 86-year-old males and females on the auditory verbal learning test
29. Sensory and perceptual performance
30. Physical performance
31. Vulnerability factors for age-related cognitive decline
32. Age-associated cognitive decline is related to biological life events
33. Age-related decline of psychomotor speed: effects of age, brain health, sex and education
34. Primitive reflexes in Alzheimer’s disease and vascular dementia
35. Next steps in describing aging and disease in longitudinal studies
36. Epidemiologic considerations in studies of cognitive function in the elderly: methodology and non-dementing acquired dysfunction
37. Relations among age, visual memory, and resting cerebral metabolism in 40 healthy men
38. Health screening and random recruitment for cognitive aging research
39. Is blood pressure an important variable in research on aging and neuropsychological test performance?
40. Desglycinamide-(Arg(8))-vasopressin in five trials with memory-disturbed patients
41. Human aging: usual and successful
42. The measurement of individual differences in aging: the distinction between usual and successful aging
43. Mental illness and hospital usage in the elderly: a random sample followed up
44. The problem of mild dementia
45. The epidemiology of Alzheimer’s disease
46. Evaluation of patients with progressive intellectual deterioration
47. Preventable dementia: a call for action against the vascular dementias
48. Outcome of investigation of patients with presenile dementia
49. The investigation of dementia: results in 200 consecutive admissions
50. The reversible dementias: do they reverse?
51. Diagnostic evaluation of 200 elderly outpatients with suspected dementia
52. On the rationale behind treatment studies in cognitive aging and dementia
53. Public education about normal forgetfulness and dementia: importance and effects
54. Public education about normal forgetfulness and dementia: effectiveness of a systematically developed information brochure
55. Memory clinic for the early diagnosis of dementia
56. Prodromal symptoms of dementia
57. Subclinical dementia. Relation to cognition, personality and psychopathology: a nine-year prospective study
58. Psychopathology of very mild dementia of the Alzheimer type
59. Personality changes in Alzheimer’s disease
60. Personality changes in Alzheimer’s disease
61. Personality alterations in dementia of the Alzheimer type
62. The progression of personality changes in patients with mild senile dementia of the Alzheimer type
63. Memory complaints in older adults. Fact or fiction?
64. The validity of memory complaints by elderly people
65. Screening for early dementia using memory complaints from patients and relatives
66. Do subjective memory complaints precede dementia? A three year follow-up study of patients with supposed ‘benign senescent forgetfulness’
67. Memory complaints and impairment in normal, depressed and demented elderly persons identified in a community survey
68. Subjective memory complaints in geriatric depression
69. The neurology of aging and dementia
70. Neurological findings in Alzheimer’s disease and normal aging
71. Very mild senile dementia of the Alzheimer type: 2. Psychometric test performance
72. Very mild senile dementia of the Alzheimer type: 1. Clinical assessment
73. Detection in life of confirmed Alzheimer’s disease using a simple measurement of medial temporal lobe atrophy by computed tomography
74. Hippocampal atrophy on magnetic resonance imaging in Alzheimer’s disease and normal aging
75. Volumetric MRI analysis of the amygdala and the hippocampus in subjects with age-associated memory impairment: correlation to visual and verbal memory
76. Establishment of diagnostic validity in psychiatric illness: its application to schizophrenia
77. Dementia, depression and awareness
78. Clinical subtypes of dementia of the Alzheimer type
79. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA workgroup under the auspices of the department of Health and Human Services task force on Alzheimer’s disease
80. Vascular dementia: diagnostic criterion for research studies. Report of the NINAIREN international workshop
81. CAMDEX: a standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia
82. Cerebral blood flow in dementia
83. Evolution of cognitive decline in dementia
84. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer’s Disease Diagnostic and Treatment Centers
85. Neuro-psychiatric observations in an old people’s home
86. The Global Deterioration Scale for assessment of primary degenerative dementia
87. A new rating scale for the staging of dementia
88. Age-associated memory impairment: proposed diagnostic criteria and measures of clinical change. Report of a National Institute of Mental Health work group
89. Criteria for diagnosing age-associated memory impairment: proposed improvements from the field
90. Should aging-associated cognitive decline be included in DSM-IV?
91. Now is the time to retire the term ‘organic mental disorders’
92. Concepts of memory impairment in the elderly and their relationship to dementia — a review
93. Senescent forgetfulness: benign and malignant
94. Age-associated memory impairment, benign forgetfulness and dementia
95. Age-associated memory impairment: a role for catecholamines
96. The age-associated memory impairment construct revisited
97. The fate of organic mental disorders in DSM-VI: a progress report
98. A proposal for DSM-IV: solving the ‘organic-nonorganic’ problem
99. Reliability of clinical criterion for the diagnosis of dementia
100. Cognitive deficits and clinical diagnosis of Alzheimer’s disease
101. The accuracy of early diagnosis and predictors of death in Alzheimer’s disease and vascular dementia — a follow-up study
102. The reliability of the Washington University Clinical Dementia Rating
103. Mild senile dementia of the Alzheimer type. 3. Longitudinal and cross-sectional assessment
104. Clinical issues relating to the diagnosis of mild dementia in a British community survey
105. A follow-up study of dementia diagnosed in the community using the Cambridge Mental Disorders of the elderly examination
106. Clinical staging of dementia in a population survey: comparison of DSM-III-R and the Washington University Clinical Dementia Rating scale
107. A study of mild dementia in the community using a wide range of diagnostic criterion
108. Memory self-knowledge and self-efficacy in the aged
109. Memory and metamemory: a study of the feeling-of-knowing phenomenon in amnestic patients
110. Subjective memory assessment and test performance in elderly adults
111. Depression in patients referred to a dementia clinic: a three year prospective study
112. Detection of abnormal memory decline in mild cases of Alzheimer’s disease using CERAD neuropsychological measures
113. Non-cognitive symptoms and the diagnosis of dementia: history and clinical aspects
114. Noncognitive symptoms of Alzheimer’s disease
115. Noncognitive symptoms in Alzheimer’s disease: definitions, treatments and possible etiologies
116. Normal ageing, impaired cognitive function, and senile dementia of the Alzheimer’s type: a continuum?
117. Pseudodementia
118. Long term follow-up of depressive pseudodementia
119. First symptoms of dementia: a study of relatives’ reports
120. Development of dementing illnesses in an 80-year-old volunteer cohort
121. Clinico-pathological studies in dementia: nondemented subjects with pathologically confirmed Alzheimer’s disease
122. Epidemiology of AD: impact on the treatment
123. The epidemiology of dementia and Alzhmeimer’s disease
124. Subtypes in Alzheimer’s disease and the impact of excess disability: recent findings
125. Heterogeneity in senile dementia of the Alzheimer type: individual differences, progressive deterioration or clinical subtypes?
126. Gene dose of apolipoprotein E Type 4 allele and the risk of Alzheimer’s disease in late onset families
127. A potential noninvasive neurobiological test for Alzheimer’s disease
128. Tacrine as a treatment for Alzheimer’s Dementia. An interim report from the FDA
129. Development of drugs for Alzheimer therapy: a decade of progress
130. Psychopharmacological perspective of cognitive functions
131. Assessing treatment effects: a neuropsychological battery
132. Tetrahydroaminoacridine and Alzheimer’s disease
133. Is treating memory impairment in Alzheimer’s disease an objective?
134. Tetrahydroamineacridine and lecithine in treatment of Alzheimer’s disease: effect on cognition, functioning in daily life, behavioral disturbances and burden experienced by the carers
135. Pharmacotherapy of cognitive deficits in Alzheimer’s disease and age associated memory impairment
136. Information processing in depression and anxiety
137. Priming and cued recall in elderly, alcohol intoxicated and sleep deprived subjects: a case of functionally similar memory deficits
138. Avoiding and managing anticholinergic effects of antidepressants
139. 1A agonists on learning and memory
140. The Influence of antihistamines on human performance
141. Acrivastine, terfenadine and diphenhydramine effects on driving performance as a function of dose and time after dosing
142. Effects of NMDA modulation in scopolamine dementia
143. TRH attenuates scopolamine-induced memory impairment in humans
144. Scopolamine and benzodiazepine models of dementia: cross-reversals by Ro 15-1788 and physostigmine
145. The effects of D-cycloserine, a glycine agonist, in a human model of the cognitive deficits associated with ageing and dementia
146. Effects of acute doses of oxiracetam in the scopolamine model of human amnesia
147. The use of a scopolamine model to study the potential nootropic effects of aniracetam and piracetam in healthy volunteers
148. Distinguishing between attentional and amnestic effects in information processing: the separate and combined effects of scopolamine and nicotine on verbal free recall
149. The separate and combined effects of scopolamine and nicotine on human information processing
150. Acute behavioral effects of triazolam and caffeine, alone and in combination, in humans
151. Antagonistic effects of caffeine and alcohol on mental performance parameters
152. Does caffeine intake enhance absolute levels of cognitive performance?
153. Relation between nicotine intake and Alzheimer’s disease
154. Evidence for a central cholinergic effect of high-dose thiamine
155. Vitamin B-6 supplementation in elderly men: effects on mood, memory, performance and mental effort
156. Lower blood levels of vitamin B12 are related to decreased performance of healthy subjects in the Stroop Color Word Test
157. Levels of trace elements in blood in healthy ageing subjects
158. Biological risk factors for accelerated cognitive aging and dementia: findings from a multiple cohort study
159. Decreased blood level of zinc: does it explain age-associated-memory-impairment?
160. Aging-associated cognitive decline: working party of the International Psychogeriatric Association in collaboration with WHO